Literature DB >> 234787

Aerosol BCG treatment of carcinoma metastatic to the lung: a phase I study.

F B Garner, C A Meyer, D S White, A Lipton.   

Abstract

BCG (TICE) was safely administered to 15 patients with metastatic cancer to the lungs in weekly doses of up to 3 X 107 organisms by the aerosol route. The aerosol route of administration is associated in approximately 33% of the doses with a toxicity syndrome of malaise, fever, and chills beginning 4 to 8 hours after treatment and ending within 24-36 hours. This syndrome is experienced by all patients and symptoms gradually subside with continuation of therapy. No hepatic or pulmonary toxicity was documented during the 221 treatment doses.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 234787     DOI: 10.1002/1097-0142(197504)35:4<1088::aid-cncr2820350411>3.0.co;2-2

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  Bacillus Calmette-Guérin vaccination using a microneedle patch.

Authors:  Yasuhiro Hiraishi; Subhadra Nandakumar; Seong-O Choi; Jeong Woo Lee; Yeu-Chun Kim; James E Posey; Suraj B Sable; Mark R Prausnitz
Journal:  Vaccine       Date:  2011-01-28       Impact factor: 3.641

2.  Pulmonary Mycobacterium bovis BCG vaccination confers dose-dependent superior protection compared to that of subcutaneous vaccination.

Authors:  Nacho Aguilo; Ana Maria Toledo; Eva Maria Lopez-Roman; Esther Perez-Herran; Eamonn Gormley; Joaquin Rullas-Trincado; Iñigo Angulo-Barturen; Carlos Martin
Journal:  Clin Vaccine Immunol       Date:  2014-02-05

3.  Intranasal administration of Mycobacterium bovis BCG induces superior protection against aerosol infection with Mycobacterium tuberculosis in mice.

Authors:  Steven C Derrick; Kristopher Kolibab; Amy Yang; Sheldon L Morris
Journal:  Clin Vaccine Immunol       Date:  2014-08-20

4.  Immunotherapy and chemoimmunotherapy of malignant disease with BCG and nonviable mycobacterial fractions.

Authors:  M A Schwarz; J U Gutterman; E M Hersh; S P Richman; G M Mavligit
Journal:  World J Surg       Date:  1977-09       Impact factor: 3.352

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.